Abeona Therapeutics (NASDAQ:ABEO) Upgraded to “Hold” at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Monday.

ABEO has been the topic of several other research reports. Oppenheimer began coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Abeona Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $17.50.

Abeona Therapeutics Trading Down 2.3 %

Shares of ABEO opened at $5.00 on Monday. Abeona Therapeutics has a twelve month low of $3.05 and a twelve month high of $8.45. The firm has a market capitalization of $217.36 million, a P/E ratio of -1.86 and a beta of 1.79. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The stock’s fifty day simple moving average is $5.43 and its 200 day simple moving average is $5.82.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.19. On average, equities research analysts forecast that Abeona Therapeutics will post -1.16 earnings per share for the current year.

Hedge Funds Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new stake in Abeona Therapeutics in the fourth quarter valued at approximately $520,000. Western Standard LLC boosted its stake in shares of Abeona Therapeutics by 22.8% in the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock valued at $11,610,000 after purchasing an additional 386,321 shares during the period. Squarepoint Ops LLC acquired a new stake in Abeona Therapeutics during the 4th quarter valued at $67,000. Twinbeech Capital LP purchased a new stake in Abeona Therapeutics during the 4th quarter worth $58,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Abeona Therapeutics in the 4th quarter worth $362,000. 80.56% of the stock is owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.